// App-Quantinova.ai

4073 : A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response.

Researchers

Presenter

  • Stephen Lam Chan

Principal Investigators

  • Winnie Yeo

  • Anthony WH Chan

  • Edwin Pun Hui

  • Paul B. S. Lai

  • Tony Mok

  • Anthony T. C. Chan

  • Simon Yu

  • Frankie Mo

  • Leung Li

  • Kit Fai Lee

Medical Centers

  • Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong

  • Chinese University of Hong Kong, Shatin, Hong KongDepartment of Diagnostic Imaging and Interventional Radiology, The Chinese University of Hong Kong, Shatin, Hong KongDepartment of Surgery, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, Hong Kong

  • Sir YK Pao Center for Cancer, State Key Laboratory in Oncology in South China, Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong

  • Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong

  • The Chinese University of Hong Kong, Hong Kong, Hong Kong

  • Partner State Key Laboratory of Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

  • Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong

Locations

  • Hong Kong

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Inlyta

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved